Skip to main content
Presentation
Efficacy and safety of brodalumab in psoriatic arthritis: 16-week results from the Phase III AMVISION-1 study. 26th Congress European Academy of Dermatology and Venereology (EADV), Geneva, Sept. 2017.
26th Congress European Academy of Dermatology and Venereology (EADV) (2017)
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
September, 2017
Citation Information
Philip Mease and et.al.. "Efficacy and safety of brodalumab in psoriatic arthritis: 16-week results from the Phase III AMVISION-1 study. 26th Congress European Academy of Dermatology and Venereology (EADV), Geneva, Sept. 2017." 26th Congress European Academy of Dermatology and Venereology (EADV) (2017)
Available at: http://works.bepress.com/philip-mease/212/